VE 465

Known as: VE-465 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2013
012320082013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Radiotherapy has been integrated into the multimodal treatment of hepatocellular carcinoma (HCC), especially of localized hepatic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Glioblastoma multiforme (GBM) is one of the most common and aggressive types of primary brain tumor. After complete surgical… (More)
Is this relevant?
2011
2011
Aurora kinases play an essential role in the regulation of mitosis. The kinases are overexpressed in a variety of cancer cells… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Aurora kinases represent promising novel cancer therapy targets. Genomic analyses of human cutaneous melanoma (CMM) models (N… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • table 1
Is this relevant?
2009
2009
BACKGROUND/AIMS Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and novel therapies are urgently… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
This study characterized the preclinical anti-myeloma activity of VE465, a low molecular weight pan-Aurora kinase inhibitor… (More)
  • figure 1
  • figure 2
Is this relevant?
2009
2009
Aurora kinases are essential for mitosis and are candidate targets of novel chemotherapeutic agents. The inhibitors ZM447439, MK… (More)
Is this relevant?
2008
2008
The expression of RHAMM and other centrosome-associated genes are known to correlate with the extent of centrosome amplification… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
A large percentage of patients with recurrent ovarian cancer develop resistance to the taxane class of chemotherapeutics. While… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2008
2008
Despite promising results from clinical studies of ABL kinase inhibitors, a challenging problem that remains is the T315I… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?